Business Context and Reporting Period
RXi Pharmaceuticals Corporation (Phio Pharmaceuticals Corp.) filed this Form 8-K on April 9, 2018, reporting the entry into a Material Definitive Agreement. The company, incorporated in Delaware, is based in Marlborough, Massachusetts. The primary event reported is a capital raise transaction that closed on April 11, 2018.
Key Financial Metrics and Transaction Details
- Common Stock Offering: Sold 1,510,604 shares at $3.15 per share.
- Warrant Issuance: Issued warrants exercisable for 1,132,953 shares (75% of common shares sold) at an exercise price of $3.15 per share. The purchase price for these warrants was $0.125 per underlying share.
- Placement Agent Fees: H.C. Wainwright & Co., LLC was engaged as the exclusive placement agent. Fees include 7.5% of gross proceeds, a 1% management fee, $25,000 for non-accountable expenses, and $100,000 for legal and out-of-pocket expenses.
- Placement Agent Warrants: Granted warrants to purchase up to 5% of the aggregate shares sold, with an exercise price of $4.0546 per share and a five-year term.
The filing text does not provide a clear value for total gross proceeds, net proceeds, current cash flow, revenue, profit margins, or existing debt levels.
Material Changes
This filing represents a material change in the company's capital structure through the issuance of new equity and warrants. The transaction involves a registered offering of common stock under a Form S-3 shelf registration and an unregistered private placement of warrants under Section 4(a)(2) and Rule 506 exemptions.
Outlook, Risks, and Contingencies
- Registration Obligation: The Company agreed to register the Warrant Shares within 30 calendar days of April 9, 2018.
- Warrant Terms: Investor warrants expire on the earlier of five years after the registration statement for Warrant Shares becomes effective or the 5.5-year anniversary of issuance. Placement Agent Warrants have a fixed five-year term.
- Legal Opinion: An opinion regarding the validity of the securities issued was provided by Gibson, Dunn & Crutcher LLP.
Investor Verification Checklist
- Verify the total gross proceeds calculated from the 1,510,604 shares sold at $3.15 and the warrant purchase price.
- Confirm the net proceeds after deducting the 7.5% placement fee, 1% management fee, and fixed expense reimbursements.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and ownership limitations.
- Check the status of the registration statement for the Warrant Shares to ensure compliance with the 30-day filing requirement.
- Assess the dilution impact of the 1,132,953 investor warrants and the placement agent warrants.